The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

Published Date: 08 Apr 2024

In three trials, the response rate was about half the patients, and it lasted for up to 19 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Pancreatic cancer RNA vaccine shows durable T cell immunity

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Exercise can counter detrimental effects of cancer treatment, review suggests

4.

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.

5.

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot